Barrow, Hanley, Mewhinney & Strauss
SRDX

Barrow, Hanley, Mewhinney & Strauss’s Surmodics SRDX Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio SRDX Stock Details SRDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-69
Closed -$2.05K – 385
2025
Q2 		$2.05K Buy
+69
New +$1.99K ﹤0.01% 295

Other funds holding SRDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's SRDX Position: Q3 2025 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Surmodics (SRDX) in Q3 2025, closing a stake of 69 shares — an estimated $2.05K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in SRDX in Q2 2025 and held it in 1 quarter. The position peaked at $2.05K in Q2 2025. 146 funds tracked by Wall St. Rank hold SRDX as of Q3 2025.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Surmodics position as of Q3 2025 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 69 Surmodics shares in Q3 2025, an estimated $2.05K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Surmodics in Q2 2025 and held it in 1 quarter.
  • Barrow, Hanley, Mewhinney & Strauss's Surmodics position peaked at $2.05K in Q2 2025.
  • 146 funds tracked by Wall St. Rank held Surmodics as of Q3 2025.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q3 2025, filed 13 Nov 2025.